Received 906 million yen in dividends from the consolidated subsidiary PharmaErase Co., Ltd. and two other subsidiaries. The dividends were decided by the subsidiary shareholders meeting on August 18, Reiwa 8 (2026), and the receipt date was August 19, Reiwa 8. No impact on the company\u2019s annual standalone results or on consolidated earnings.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2796","jir_company_name":"Pharamarize Holdings Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-18","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/2796-20260818-01.pdf","jir_short_summary":"Received 906 million yen in dividends from the consolidated subsidiary PharmaErase Co., Ltd. and two other subsidiaries. The dividends were decided by the subsidiary shareholders meeting on August 18, Reiwa 8 (2026), and the receipt date was August 19, Reiwa 8. No impact on the company\u2019s annual standalone results or on consolidated earnings.","jir_summary":"### Dividend overview\nWe announce that we received a total of 906 million yen in dividends from consolidated subsidiaries PharmaErase Co., Ltd. and two other companies. The dividend resolution date was August 18, Reiwa 8, when the subsidiary shareholders meeting was held, and the receipt date is August 19, same year. Since the dividend comes from consolidated subsidiaries, it does not affect our earnings (consolidated).\n\n### Impact on earnings\nIn the May quarter for Reiwa 9, the dividend will be recorded as operating revenue in the standalone financial statements. The impact on consolidated earnings is stated as none.","jir_financial_highlights":"Dividend amount: 906 \u767e\u4e07\u5186 (Unknown)\nPayers: PharmaErase Co., Ltd., and two other companies (Unknown)\nDividend receipt date: \u4ee4\u548c\uff18\u5e74\uff18\u670819\u65e5 (Unknown)","jir_category":"","jir_hashtags":"#PharmaErase Holdings, #Dividend, #IRNews","jir_key_figures":"Dividend amount: 906 \u767e\u4e07\u5186\nPayers: PharmaErase Co., Ltd., and two other companies\nDividend resolution date: \u4ee4\u548c\uff18\u5e74\uff18\u670818\u65e5\nDividend receipt date: \u4ee4\u548c\uff18\u5e74\uff18\u670819\u65e5","jir_meta_title":"\u3010PharmaErase Holdings\u3011Notice of Dividend Receipt from Consolidated Subsidiaries\uff5cAugust 2026","jir_meta_description":"PharmaErase Holdings received a dividend from consolidated subsidiaries. Amount is 906 million yen, receipt date is August 19, 2026. No impact on standalone results, no impact on consolidated results. Pay attention to future earnings outlook.","jir_og_title":"\u3010PharmaErase Holdings\u3011Notice of Dividend Receipt from Consolidated Subsidiaries\uff5cAugust 2026","jir_og_description":"Total dividend of 906 million yen from consolidated subsidiaries received. Key points include receipt date, resolution date, and the absence of impact on consolidated and standalone earnings.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59671,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"dividend","footnotes":""},"sector":[],"importance":[],"class_list":["post-105133","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n